Sapitinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sapitinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Sapitinib can convert its Small molecule drug profile and EGFR x HER2 x HER3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sapitinib (query alias: Sapitinib) |
|---|---|
| Modality / target | Small molecule drug; EGFR x HER2 x HER3; EGFR antagonists, HER2 antagonists, HER3 antagonists |
| Highest global status | Phase 2 |
| Originator | AstraZeneca Pharmaceuticals Co. Ltd. |
| Active developers | AstraZeneca Pharmaceuticals Co. Ltd., AstraZeneca PLC |
The MCP disease footprint includes Metastatic breast cancer, Colorectal Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| EUCTR2012-005111-12-GB | Phase 2/3 | GB - no longer in EU/EEA | 4200 | There are no primary outcome measures for the registration period as no interventions are being compared during this period. The primary outcome measure for the subsequent FOCUS4 comparisons that commence at the end of the registration period will be Progression-Free Survival (PFS) defined as progression of disease according to RECIST v1.1 criteria or death from any cause. Analysis will be timed from randomisation with the baseline CT scan performed within 4 weeks prior to randomisation. For trials that complete Stage III, at this point, a decision will be made on whether to revise power calculations to include Overall Survival (OS) as an additional primary outcome measure. |
| NCT02299999 | Phase 2 | Active, not recruiting | 1460 | Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm |
| NCT02117167 | Phase 2 | Completed | 999 | progression-free survival in the targeted drug arm compared to standard maintenance therapy arm |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Phase 1/2; n=18; evaluation: Positive. Reported fields: BOR = 25 %
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma
Phase 1; n=24; evaluation: not stated. Reported fields: -; RP2D(recommended phase II dose) = 20 mg
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer
Phase 2; n=359; evaluation: Negative. Reported fields: mPFS = 13.8 month ; mPFS = 10.9 month ; mPFS = 14.0 month
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sapitinib addresses Metastatic breast cancer, Colorectal Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 172 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: EGFR x HER2 x HER3 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-21 | 27.6亿元！同源康与齐鲁制药达成战略投资与授权协议 | NDA/BLA | US$10.3M upfront; US$304.4M milestones |
| 2026-07-14 | Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy | Approved | US$600.0M upfront; US$900.0M milestones |
| 2026-05-18 | 全面强化肺癌治疗版图！复宏汉霖引进正大丰海/江苏创特三代口服EGFR-TKI | NDA/BLA | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Use of an RXR agonist in treating drug resistant her2+ cancers”. The milestone feed surfaced a patent-application signal described as “ERK1/2 and EGFR inhibitors combination therapy”. The milestone feed surfaced a patent-application signal described as “PCNA inhibitors and EGFR inhibitors for cancer treatment”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
